Thu. 21 Mar 2024, 4:20pm ET
Benzinga
Earnings, News
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 11.32 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $2.09 million which beat the analyst consensus estimate of $1.71 million by 22.16 percent. This is a 48.05 percent increase over sales of $1.41 million the same period last year.